At ACC 2026, the phase II CADENCE trial reported results for sotatercept (WINREVAIR) in adults with combined post- and precapillary pulmonary hypertension associated with HFpEF.
At the 2026 ACC Scientific Session, the phase II KARDINAL trial tested tonlamarsen in adults with uncontrolled hypertension, comparing single versus monthly dosing on blood pressure and a key biomarker.
Teva Pharmaceutical has announced the US FDA approval for Ponlimsi as a biosimilar to Prolia, alongside the acceptance of its biosimilar candidate applications for Xolair by both the agency and the EMA.
uBriGene Biosciences has partnered with Cellinfinity BIO to advance the clinical development of in vivo CAR-T therapy programmes for haematologic and solid tumours.
At the 2026 ACC Scientific Session in New Orleans, researchers presented a meta-analysis of three randomized trials (1,264 patients) evaluating baxdrostat’s blood pressure effects and safety in patients with uncontrolled hypertension on standard therapy.
At the 2026 ACC Scientific Session in New Orleans, Brazilian investigators presented a meta-analysis of three placebo-controlled trials (1,060 patients) assessing lorundrostat’s blood pressure and safety effects in uncontrolled hypertension.
In this Q&A with Grace Breen, SVP, Quality, Sharp, we explore the defining moments that have shaped her understanding of what quality means for pharma.
